Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

C. Difficile Prophylactic Program Remains on Track

August 5, 2014 3:01 pm | News | Comments

Synthetic Biologics Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced that, with a new multi-service agreement in place, the company is on track to initiate Phase 1a and 1b clinical trials of SYN-004 for the prevention of Clostridium difficile. Read more...

TOPICS:

Nanoscale Thin-Film Technique Promises Long-Term Drug Delivery

August 5, 2014 2:50 pm | by Peter Dizikes, MIT News Office | News | Comments

About one in four older adults suffers from chronic pain. Many of those people take medication, usually as pills. But this is not an ideal way of treating pain: Patients must take medicine frequently, and can suffer side effects, since the contents of pills spread through the bloodstream to the whole body. Read more...

TOPICS:

IPF Drug Receives Orphan Drug Designation

August 5, 2014 2:38 pm | News | Comments

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, announced the U.S. Food and Drug Administration has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program - inhaled GP-101 for the treatment of idiopathic pulmonary fibrosis (IPF). Read more...

TOPICS:
Advertisement

Paclitaxel Reformulated for Bolus Intraperitoneal Injection

August 5, 2014 2:30 pm | News | Comments

A repurposed drug originally used to treat ovarian cancer saw positive results for patients with advanced peritoneal cancers during a phase 1 clinical trial at The University of Kansas Cancer Center, during which it was administered as a bolus injection directly into the peritoneum through a catheter. Read more...

TOPICS:

Paradigm Kicks Off Genomic Profiling for Cancer Registry

August 5, 2014 2:16 pm | News | Comments

Paradigm has announced they have initiated genomic testing for Pharmatech's AccessPPM Cancer Registry, which is designed to collect EMR data and genomic information to help best match cancer patients with targeted clinical trials. Read more... 

TOPICS:

Scientists Use Subcellular Imaging to Visualize Glutamate Receptors

August 5, 2014 2:08 pm | News | Comments

Scientists at the National Institutes of Health have created high-resolution images of the glutamate receptor, a protein that plays a key role in nerve signaling. The advance, published online in the journal Nature, opens a new window to study protein interactions in cell membranes in exquisite detail. Read more...

TOPICS:

Novimmune to Start Proof of Concept Study for RA Drug

August 5, 2014 11:02 am | News | Comments

Novimmune SA announced the completion of a comprehensive Phase 1 clinical trial investigating the pharmacokinetics, pharmacodynamics, preliminary tolerability and safety of NI-0101, a first-in-class monoclonal antibody against toll-like receptor 4, in presence and absence in vivo of a TLR4 ligand. Read more...

TOPICS:

Parkinson's Drug Eligible for EU Centralized Procedure

August 5, 2014 10:57 am | News | Comments

NeuroDerm Ltd. announced that the European Medicines Agency has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). Read more...

TOPICS:
Advertisement

Glioblastoma Triple Therapy Revs Up Immune System

August 5, 2014 10:52 am | News | Comments

A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report by scientists at the Johns Hopkins Kimmel Cancer Center. Read more...

TOPICS:

Muscular Dystrophy Drug Conditionally Approved

August 5, 2014 10:47 am | News | Comments

PTC Therapeutics Inc. announced that the European Commission has granted conditional marketing authorization for Translarna (ataluren), in the European Union for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Read more...

TOPICS:

Global Research Team Advances Insulin Therapy

August 5, 2014 10:41 am | News | Comments

Since its landmark discovery in 1922, insulin has improved the health and extended the lives of more than 500 million people worldwide with diabetes mellitus, yet the question of how this key hormone binds to its target cells in the body’s organs has posed an enduring scientific mystery. Read more...

TOPICS:

US Gov’t, Military Spotted Ebola Drug

August 5, 2014 10:35 am | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

Two American aid workers infected with Ebola are getting an experimental drug so novel it has never been tested for safety in humans and was only identified as a potential treatment earlier this year, thanks to a longstanding research program by the U.S. government and the military. Read more...

TOPICS:

BMS, Allied Minds Form Unique Research Enterprise

August 4, 2014 2:52 pm | News | Comments

Allied Minds and Bristol-Myers Squibb Co. announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the United States. Read more...

TOPICS:

Isis Initiates Phase 3 Infant SMA Study

August 4, 2014 2:40 pm | News | Comments

Isis Pharmaceuticals Inc. announced the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Read more...           

TOPICS:

Jentadueto Gets Label Update with New Trial Info

August 4, 2014 2:27 pm | News | Comments

The U.S. Prescribing Information for Jentadueto tablets now includes clinical trial data that showed linagliptin co-administered with metformin provided statistically significant decreases in blood glucose compared with linagliptin alone. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading